Maintenance Infos

Browse by Creators

Navigate back| Up a level
Export as
Number of items: 11.

Kolios, A G A; Hueber, A J; Michetti, P; Mrowietz, U; Mustak-Blagusz, M; Sator, P-G; Reinshagen, M; Wilsmann-Theis, D; Gomis-Kleindienst, S; Luckey, U; Rössler, A; Schiefke, I (2019). ALIGNed on adherence: subanalysis of adherence in immune-mediated inflammatory diseases in the DACH region of the global ALIGN study. Journal of the European Academy of Dermatology and Venerology, 33(1):234-241.

Vavricka, S R; Spigaglia, S M; Rogler, G; Pittet, V; Michetti, P; Felley, C; Mottet, C; Braegger, C P; Rogler, D; Straumann, A; Bauerfeind, P; Fried, M; Schoepfer, A M (2011). Systematic evaluation of risk factors for diagnostic delay in inflammatory bowel disease. Inflammatory Bowel Diseases, 18(3):496-505.

Vavricka, S R; Schoepfer, A M; Bansky, G; Binek, J; Felley, C; Geyer, M; Manz, M; Rogler, G; de Saussure, P; Sauter, B; Scharl, M; Seibold, F; Straumann, A; Michetti, P (2011). Efficacy and safety of certolizumab pegol in an unselected crohn's disease population: 26-week data of the FACTS II survey. Inflammatory Bowel Diseases, 17(7):1530-1539.

Schoepfer, A M; Vavricka, S R; Binek, J; Felley, C; Geyer, M; Manz, M; Rogler, G; de Saussure, P; Sauter, B; Seibold, F; Straumann, A; Michetti, P (2010). Efficacy and safety of certolizumab pegol induction therapy in an unselected Crohn's disease population: Results of the FACTS survey. Inflammatory Bowel Diseases, 16(6):933-938.

Pittet, V; Juillerat, P; Michetti, P; Vader, J P; Burnand, B; Rogler, G; Beglinger, C; Seibold, F; Mottet, C; Felley, C; Gonvers, J J; Froehlich, F; et al; Braegger, C P (2010). Appropriateness of therapy for fistulizing Crohn's disease: findings from a national inflammatory bowel disease cohort. Alimentary Pharmacology & Therapeutics, 32(8):1007-1016.

Nichita, C; Stelle, M; Vavricka, S; El-Wafa Ali, A; Ballabeni, P; de Saussure, P; Straumann, A; Rogler, G; Michetti, P (2010). Clinical experience with Adalimumab in a multicenter Swiss cohort of patients with Crohn's disease. Digestion, 81(2):78-85.

Juillerat, P; Pittet, V; Vader, J P; Burnand, B; Gonvers, J J; de Saussure, P; Mottet, C; Seibold, F; Rogler, G; Sagmeister, M; Felley, C; Michetti, P; Froehlich, F; et al; Braegger, C P (2010). Infliximab for Crohn's disease in the Swiss IBD Cohort Study: clinical management and appropriateness. European Journal of Gastroenterology & Hepatology, 22(11):1352-1357.

Szucs, T D; Thalmann, C; Michetti, P; Beglinger, C (2009). Cost Analysis of Long-Term Treatment of Patients with Symptomatic Gastroesophageal Reflux Disease (GERD) with Esomeprazole On-Demand Treatment or Esomeprazole Continuous Treatment: An Open, Randomized, Multicenter Study in Switzerland. Value in Health, 12(2):273-281.

Pittet, V; Juillerat, P; Mottet, C; Felley, C; Ballabeni, P; Burnand, B; Michetti, P; Vader, J P (2009). Cohort profile: the Swiss Inflammatory Bowel Disease Cohort Study (SIBDCS). International Journal of Epidemiology, 38:922-931.

Beglinger, C; Binek, J; Braegger, C; Michetti, P; Rogler, G; Sauter, B; Seibold, F; Straumann, A (2008). Infliximab-Monotherapie versus Kombinationstherapie mit Immunmodulatoren : Aktuelle Therapieempfehlungen einer Schweizer Expertengruppe. Medical Journal (TMJ), (1):32-34.

Beglinger, C; Thalmann, C; Szucs, T; Michetti, P (2006). Long-term treatment of patients with symptomatic gastroesophageal reflux disease comparing costs and efficacy over 6 months of treatment with Nexium On-Demand Treatment or Nexium continuous treatment. An open, randomised multi-center study. Praxis, 95(13):483-487.

This list was generated on Tue May 21 18:49:51 2019 CEST.